<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><description>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 24 Feb 2021 14:02:20 +0800</pubDate><image><url>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</url><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>Probody抗体前药技术：增强on-target效应，降低off-tumor毒性</title><link>https://mp.weixin.qq.com/s/yP7G7EqncVUKV4qykbjSeQ</link><description></description><content:encoded><![CDATA[Probody抗体前药技术：增强on-target效应，降低off-tumor毒性]]></content:encoded><pubDate>Tue, 23 Feb 2021 14:14:15 +0800</pubDate></item><item><title>100款已上市抗体药物氨基酸序列</title><link>https://mp.weixin.qq.com/s/F9ptYErMcdn7-8vZOvaxvw</link><description></description><content:encoded><![CDATA[100款已上市抗体药物氨基酸序列]]></content:encoded><pubDate>Tue, 23 Feb 2021 14:14:15 +0800</pubDate></item><item><title>我们用这本书凝聚了中国生物医药的2020</title><link>https://mp.weixin.qq.com/s/WCsRdrnuqDrb6kGZ7o658g</link><description></description><content:encoded><![CDATA[我们用这本书凝聚了中国生物医药的2020]]></content:encoded><pubDate>Tue, 23 Feb 2021 14:14:15 +0800</pubDate></item><item><title>定了！春天不可错过的细胞治疗权威峰会就在上海！</title><link>https://mp.weixin.qq.com/s/h823S_ZtOIofzzkZXQiNoQ</link><description></description><content:encoded><![CDATA[定了！春天不可错过的细胞治疗权威峰会就在上海！]]></content:encoded><pubDate>Tue, 23 Feb 2021 14:14:15 +0800</pubDate></item><item><title>中性粒细胞介导的细胞毒作用可用于扩展基于hIgG的癌症治疗</title><link>https://mp.weixin.qq.com/s/hSwx6O9C5-htukmfgYtcPA</link><description></description><content:encoded><![CDATA[中性粒细胞介导的细胞毒作用可用于扩展基于hIgG的癌症治疗]]></content:encoded><pubDate>Mon, 22 Feb 2021 16:16:40 +0800</pubDate></item><item><title>2020年基因治疗领域大事记</title><link>https://mp.weixin.qq.com/s/S2Q-5XbPohSiPlf4Vs3LrQ</link><description></description><content:encoded><![CDATA[2020年基因治疗领域大事记]]></content:encoded><pubDate>Mon, 22 Feb 2021 16:16:40 +0800</pubDate></item><item><title>大咖云集 · 免疫细胞治疗大会4月即将开幕！</title><link>https://mp.weixin.qq.com/s/mC52jBY7Q6ZMwURahgL_Eg</link><description></description><content:encoded><![CDATA[大咖云集 · 免疫细胞治疗大会4月即将开幕！]]></content:encoded><pubDate>Mon, 22 Feb 2021 16:16:40 +0800</pubDate></item><item><title>ICHE1指导原则与创新药物临床开发案例分析</title><link>https://mp.weixin.qq.com/s/caSMrruneR1L8Jwf5ecyig</link><description></description><content:encoded><![CDATA[ICHE1指导原则与创新药物临床开发案例分析]]></content:encoded><pubDate>Sun, 21 Feb 2021 14:49:34 +0800</pubDate></item><item><title>《免疫细胞治疗产品临床试验技术指导原则（试行）》解读</title><link>https://mp.weixin.qq.com/s/7RCA6luq1SuyoGF7xKuVZQ</link><description></description><content:encoded><![CDATA[《免疫细胞治疗产品临床试验技术指导原则（试行）》解读]]></content:encoded><pubDate>Sun, 21 Feb 2021 14:49:34 +0800</pubDate></item><item><title>游方和尚专栏 | 胆汁酸与胆汁淤积性及相关疾病（一）原发性硬化性胆管炎（PSC）</title><link>https://mp.weixin.qq.com/s/CZTQvx2KCBohz8uv8QF9gA</link><description></description><content:encoded><![CDATA[游方和尚专栏 | 胆汁酸与胆汁淤积性及相关疾病（一）原发性硬化性胆管炎（PSC）]]></content:encoded><pubDate>Sat, 20 Feb 2021 18:00:32 +0800</pubDate></item><item><title>罗氏（Roche）—出过3个诺贝尔奖的公司，研发投入行业最高</title><link>https://mp.weixin.qq.com/s/TBr3YuhnIAz72YjwV45Xxw</link><description></description><content:encoded><![CDATA[罗氏（Roche）—出过3个诺贝尔奖的公司，研发投入行业最高]]></content:encoded><pubDate>Sat, 20 Feb 2021 18:00:32 +0800</pubDate></item><item><title>火热报名中！TG-Bio2021第二届免疫治疗技术大会邀您共聚申城！</title><link>https://mp.weixin.qq.com/s/gKyGW7e3JOlWUkv2TtLMGw</link><description></description><content:encoded><![CDATA[火热报名中！TG-Bio2021第二届免疫治疗技术大会邀您共聚申城！]]></content:encoded><pubDate>Sat, 20 Feb 2021 18:00:32 +0800</pubDate></item><item><title>CAR-T专利全球概况，科济生物进入Top20受让人</title><link>https://mp.weixin.qq.com/s/HvegWYgYHToohRCQoz6Lvg</link><description></description><content:encoded><![CDATA[CAR-T专利全球概况，科济生物进入Top20受让人]]></content:encoded><pubDate>Fri, 19 Feb 2021 19:45:58 +0800</pubDate></item><item><title>“睡美人” CAR-T</title><link>https://mp.weixin.qq.com/s/uHh_Yyk9H0PdvYHepU4PoA</link><description></description><content:encoded><![CDATA[“睡美人” CAR-T]]></content:encoded><pubDate>Fri, 19 Feb 2021 19:45:58 +0800</pubDate></item><item><title>即将进入倒计时！TG-Bio2021第二届免疫治疗技术大会邀您共聚申城！</title><link>https://mp.weixin.qq.com/s/5VLhQ-CuioSXw0CeMF_pVQ</link><description></description><content:encoded><![CDATA[即将进入倒计时！TG-Bio2021第二届免疫治疗技术大会邀您共聚申城！]]></content:encoded><pubDate>Fri, 19 Feb 2021 19:45:58 +0800</pubDate></item><item><title>Self Renew专栏｜BAT8001之外</title><link>https://mp.weixin.qq.com/s/VrExPaF9cL1eBceyfv2bsw</link><description></description><content:encoded><![CDATA[Self Renew专栏｜BAT8001之外]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:35:50 +0800</pubDate></item><item><title>FDA累计批准36款全人源抗体</title><link>https://mp.weixin.qq.com/s/9hMEDsDQU1_4mF6R60pIDA</link><description></description><content:encoded><![CDATA[FDA累计批准36款全人源抗体]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:35:50 +0800</pubDate></item><item><title>全面开花！B7-H3的抗体靶向治疗</title><link>https://mp.weixin.qq.com/s/2MgYVPBsNdyPAIFmYrnW6g</link><description></description><content:encoded><![CDATA[全面开花！B7-H3的抗体靶向治疗]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:35:50 +0800</pubDate></item><item><title>法规讨论-新冠疫苗审批可优化空间</title><link>https://mp.weixin.qq.com/s/bdUe7LNNOEY74tK4hDjWdQ</link><description></description><content:encoded><![CDATA[法规讨论-新冠疫苗审批可优化空间]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:35:50 +0800</pubDate></item><item><title>UPI报告出炉：药王修美乐再上榜，提价挺进200亿美元</title><link>https://mp.weixin.qq.com/s/L6CYd0eyWJOSScbmju0N2g</link><description></description><content:encoded><![CDATA[UPI报告出炉：药王修美乐再上榜，提价挺进200亿美元]]></content:encoded><pubDate>Wed, 17 Feb 2021 20:06:51 +0800</pubDate></item></channel></rss>